Is IL-6 a key cytokine target for therapy in COVID-19?

Is IL-6 a key cytokine target for therapy in COVID-19?

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonist...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Immunology 2021-06, Vol.21 (6), p.337-339
Hauptverfasser: Jones, Simon A., Hunter, Christopher A.
Format: Artikel
Sprache:eng
Schlagworte:
631/250/127/1213
631/326/596/4130
692/308/575
692/420/254
692/699/255/2514
Antagonists
Anti-inflammatory drugs
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Biological response modifiers
Biomedical and Life Sciences
Biomedicine
Clinical trials
Comment
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - immunology
COVID-19 Drug Treatment
Cytokine Release Syndrome - drug therapy
Cytokine Release Syndrome - etiology
Cytokine Release Syndrome - immunology
Cytokines
Cytokines - antagonists & inhibitors
Health aspects
Humans
Immune response
Immunological research
Immunology
Interleukin 6
Interleukin-6 - antagonists & inhibitors
Interleukin-6 - blood
Methods
Molecular targeted therapy
Receptors, Interleukin-6 - antagonists & inhibitors
SARS-CoV-2
Severity of Illness Index
Signal Transduction - drug effects
Signal Transduction - immunology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here.
ISSN:1474-1733
1474-1741
DOI:10.1038/s41577-021-00553-8